Accelerated vaccine development against emerging infectious diseases

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 1010-1012

  Leblanc, Pierre R ^a   Yuan, Jianping ^a   Brauns, Tim ^a   Gelfand, Jeffrey A ^a   Poznansky, Mark C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Emerging infectious diseases; Human artificial lymph node; Immunoinformatics; Immunomics; Immunopeptides; Immunostimulatory; Immunotoxicity; Metagenomics; Proteomics; Self assembling vaccine

Indexed keywords

ALLERGEN; ANTIBIOTIC AGENT; AVIDIN; EPITOPE; HEAT SHOCK PROTEIN 70; HLA ANTIGEN; HYBRID PROTEIN; NEW DRUG; PEPTIDE; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIGENICITY; AUTOIMMUNITY; BIOINFORMATICS; BIOTECHNOLOGY; COMPUTER MODEL; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; EMERGING INFECTIOUS DISEASE; EX VIVO STUDY; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOTOXICITY; IN VIVO STUDY; INFECTION; INFECTION RISK; INFLUENZA; MEDICAL TECHNOLOGY; NONHUMAN; NOTE; PANDEMIC; POPULATION RISK; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION; ANIMAL DISEASE; ARTICLE; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG DEVELOPMENT; IMMUNOLOGY;

COMMUNICABLE DISEASES, EMERGING; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; VACCINES;

EID: 84864049052     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20805     Document Type: Note

References (11)

1. World Health Organization. World Health Statistics 2011. World Health Organization Press, 2011.
2. Guimerà RR, Mossa SS, Turtschi AA, Amaral LANL. The worldwide air transportation network: Anomalous centrality, community structure, and cities' global roles. Proc Natl Acad Sci U S A 2005; 102:7794-9; PMID: 15911778; http://dx.doi.org/10.1073/pnas.0407994102
3. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004; 430:242-9; PMID:15241422; http://dx.doi.org/10.1038/nature02759
4. Fauci AS. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 2006; 124:665-70; PMID:16497575; http://dx.doi.org/10.1016/j.cell.2006.02.010
5. Towers S, Feng Z. Pandemic H1N1 influenza: predicting the course of a pandemic and assessing the efficacy of the planned vaccination programme in the United States. Euro Surveill 2009; 14:19358; PMID: 19883540
6. Parry J. From SARS to avian flu: Vaccines on the scene. Scientist 2005; 19:34.
7. Seib KL, Dougan G, Rappuoli R. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet 2009; 5: e1000612; PMID:19855822; http://dx.doi.org/10.1371/journal.pgen.1000612
8. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol 2010; 2010:218590; PMID:21772787
9. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29:2085-91; PMID:21236233; http://dx.doi.org/10.1016/j.vaccine. 2010.12.130
10. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID: 21055490; http://dx.doi.org/10.1016/j.vaccine. 2010.10.064
11. De Groot AS, McClaine E, Moise L, Martin W. Time for T?: Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines. Hum Vaccin 2010; 6:6; PMID:20431339; http://dx.doi.org/10.4161/hv.6.2.11333